Pembrolizumab
Locally Advanced Urethral Urothelial Carcinoma
Alliance for Clinical Trials in Oncologymonoclonal_antibodyPhase 3Active
BB
67/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 53/ 100
- Competitive Position
- 95/ 100
Competitive context
19 Active assets in the Locally Advanced Urethral Urothelial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nivolumab Nagoya University | Phase 3 | BB |
CIS-DIAMMINEDICHLOROPLATINUM II Nagoya University | Phase 3 | BB |
Cyclophosphamide Alliance for Clinical Trials in Oncology | Phase 3 | BB |
Relatlimab National Cancer Institute (NCI) | Phase 2/3 | BB |
Atezolizumab Alliance for Clinical Trials in Oncology | Phase 3 | BB |
View all 23 →
Same molecule, other indications
Pembrolizumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →